RxDoctor Payments Data

Iva Conde, APRN

Psychiatric/Mental Health · Lake Charles, LANPI 1831212943

Payments from drug & device makers

$4,799in general payments, 2019–2025

Across 79 payments — averaging $60.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$213
  • Otsuka America Pharmaceutical, Inc.$199
  • Teva Pharmaceuticals USA, Inc.$168
  • Alkermes, Inc.$143
  • Axsome Therapeutics, Inc.$87
  • plus $267 from 6 others

What the payments were for

  • Speaking & faculty fees$3,00063%
  • Travel & lodging$351%
  • Food & beverage$1,76437%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,799 in reported general payments places this provider in the 80th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana

Medicare billing

Part B allowed, 2024
$2,854
Medicare patients
18
Services billed
47

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine14$114,630
IngrezzaValbenazine Tosylate14$91,742
AustedoDeutetrabenazine15$72,750
Invega SustennaPaliperidone Palmitate29$72,354
Abilify MaintenaAripiprazole17$50,101
LybalviOlanzapine/Samidorphan Malate25$42,156
VraylarCariprazine Hcl30$38,884
CaplytaLumateperone Tosylate22$37,583
AuvelityDextromethorphan Hbr/Bupropion29$24,552
RexultiBrexpiprazole16$21,504
TrintellixVortioxetine Hydrobromide38$19,506
ZoloftSertraline Hcl21$9,650
Desvenlafaxine Succinate ErDesvenlafaxine Succinate75$8,057
BelsomraSuvorexant17$8,006
Tiagabine Hcl30$6,829

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$168$187,38129 claims
Neurocrine Biosciences, Inc.Ingrezza$86$91,74214 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$199$71,60533 claims
Alkermes, Inc.Lybalvi$143$42,15625 claims
AbbVieVraylar$3,721$38,88430 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$213$37,58322 claims
Axsome Therapeutics, Inc.Auvelity$87$24,55229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →